Last 26 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -5.24 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 19.36 | 30.96 | 24.89 | 5.06 | 17.49 | 32.63 | 36.42 | 20.31 | 10.22 | 5.61 | 6.26 | 4.48 | 10.04 |
| — | -5.1% | -31.7% | -75.1% | +71.1% | +481.8% | +482.0% | +353.9% | +1.8% | -77.2% | -66.2% | -54.8% | -46.5% | |
| P/B Ratio | 2.57 | 3.12 | 2.11 | 1.99 | 2.68 | 3.29 | 4.87 | 2.65 | 4.02 | 1.70 | 1.98 | 2.11 | 1.86 |
| — | -5.1% | -56.6% | -24.8% | -33.2% | +94.0% | +146.1% | +25.5% | +116.1% | -22.9% | -15.4% | +24.4% | -21.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | 3.53 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Nurix Therapeutics, Inc.'s operating margin was -612.0% in Q4 2025, up 545.6 pp QoQ and down 125.3 pp YoY. The trailing four-quarter average of -555.0% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 116.2% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.5% | 65.9% | 36.7% | -77.3% | -277.5% | -406.1% | -340.7% | -304.6% | -201.5% | -227.9% | -159.1% | -49.2% | -261.2% |
| — | +116.2% | +110.8% | +74.6% | -37.7% | -78.1% | -114.1% | -519.3% | +22.8% | +60.7% | +53.5% | +84.4% | +25.0% | |
| Operating Margin | -340.2% | -612.0% | -1157.7% | -109.7% | -340.7% | -486.7% | -433.8% | -401.4% | -272.7% | -299.1% | -216.7% | -87.3% | -338.6% |
| — | -25.7% | -166.8% | +72.7% | -24.9% | -62.8% | -100.2% | -360.1% | +19.5% | +58.3% | +50.0% | +78.2% | +23.8% | |
| Net Margin | -314.9% | -576.1% | -1094.8% | -98.7% | -305.4% | -440.7% | -388.9% | -368.4% | -250.3% | -276.8% | -200.3% | -79.1% | -321.1% |
| — | -30.7% | -181.5% | +73.2% | -22.0% | -59.2% | -94.2% | -365.5% | +22.0% | +59.8% | +52.7% | +80.1% | +27.4% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -49.6% | -17.2% | -21.1% | -9.4% | -11.2% | -13.0% | -13.1% | -16.5% | -22.5% | -19.3% | -15.0% | -9.1% | -14.1% |
| — | -32.6% | -61.0% | +43.3% | +50.3% | +32.9% | +12.6% | -81.6% | -59.5% | -33.6% | +0.2% | +42.7% | -7.4% | |
| ROA | -39.0% | -12.9% | -15.5% | -7.2% | -8.8% | -9.9% | -9.6% | -10.8% | -12.4% | -12.6% | -11.2% | -6.7% | -10.4% |
| — | -30.5% | -62.4% | +33.4% | +29.4% | +21.7% | +14.9% | -60.6% | -20.0% | -18.5% | -4.8% | +38.3% | -11.3% | |
| ROIC | -54.0% | -17.9% | -17.9% | -8.6% | -10.8% | -12.9% | -13.9% | -16.9% | -20.9% | -18.1% | -14.6% | -8.7% | -12.8% |
| — | -38.2% | -28.5% | +49.4% | +48.5% | +28.5% | +4.8% | -94.3% | -62.9% | -38.5% | -14.5% | +38.8% | -3.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 8.6% YoY to 7.02x, strengthening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 0.15 | 0.12 | 0.06 | 0.05 | 0.07 | 0.08 | 0.17 | 0.15 | 0.03 | 0.04 | 0.04 |
| — | +92.6% | +110.7% | +49.2% | -68.0% | -64.8% | +110.4% | +116.3% | +344.1% | +287.6% | -11.4% | -33.9% | -24.5% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 7.02 | 7.02 | 5.35 | 6.82 | 6.26 | 6.46 | 5.28 | 5.57 | 2.86 | 3.40 | 4.36 | 4.01 | 4.44 |
| — | +8.6% | +1.2% | +22.3% | +118.7% | +90.2% | +21.3% | +38.9% | -35.6% | -24.6% | -17.1% | -4.9% | +4.7% | |
| Quick Ratio | 7.02 | 7.02 | 5.35 | 6.82 | 6.26 | 6.46 | 5.28 | 5.57 | 2.86 | 3.40 | 4.36 | 4.03 | 4.46 |
| — | +8.6% | +1.2% | +22.3% | +118.7% | +90.2% | +21.3% | +38.4% | -35.8% | -24.9% | -17.4% | -4.8% | +5.1% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 26 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonNurix Therapeutics, Inc.'s current P/E is -5.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Nurix Therapeutics, Inc.'s current operating margin is -340.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Nurix Therapeutics, Inc.'s business trajectory between earnings reports.